SVELTE trial:: A multicenter, historically controlled study in patients with de novo native coronary artery lesions in small VessELs treated with the CYPHER™ sTEnt

被引：0
|
作者：
Meier, B [1 ]
机构：
[1] Univ Hosp Bern, Swiss Cardiovasc Ctr Bern, CH-3010 Bern, Switzerland
来源：
AMERICAN JOURNAL OF CARDIOLOGY | 2003年 / 92卷 / 6A期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：91L / 92L
页数：2
相关论文
共 50 条
  • [41] Five-year clinical outcome of multicenter randomized trial comparing amphilimus - with paclitaxel-eluting stents in de novo native coronary artery lesions
    Carrie, Didier
    Berland, Jacques
    Verheye, Stefan
    Hauptmann, Karl Eugen
    Vrolix, Mathias
    Musto, Carmine
    Berti, Sergio
    Dibie, Alain
    Maupas, Eric
    Antoniucci, David
    Schofer, Joachim
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2020, 301 : 50 - 55
  • [42] Nine-month results of the TROPICAL study:: a multicenter nonrandomized study of the Cypher™ sirolimus-eluting stent in the treatment of patients with an instent restenotic native coronary artery lesion
    Desmet, W
    Neumann, FJ
    Krozingen, B
    Grube, E
    Brachmann, J
    Coburg, K
    Presbitero, P
    Rubartelli, P
    Muegge, A
    Di Pede, F
    Fuellgraf, D
    Aengevaeren, W
    Spedicato, L
    CIRCULATION, 2004, 110 (17) : 406 - 406
  • [43] A European and a Canadian multicenter randomized, double-blind trial of the sirolimus-eluting stent (SES) in patients with de novo native coronary artery lesions (NEW-SIRIUS):: 4-year clinical outcomes
    Schampaert, Erick
    Schofer, Joachim
    Breithardt, Gunter
    Cohen, Eric A.
    Schluter, Michael
    Wichter, Thomas
    AMERICAN JOURNAL OF CARDIOLOGY, 2006, 98 (8A): : 156M - 156M
  • [44] A European and Canadian multicenter randomized, double-blind trial of the Sirolimus-Eluting Stent (SES) in patients with de novo native coronary artery lesions (NEW-SIRIUS):: 5-year clinical outcomes
    Schampaert, Eric
    Schofer, Joachim
    Breithardt, Guenther
    Cohen, Eric A.
    Schlueter, Michael
    Wichter, Thomas
    Wittelbols, Kristel
    Stoll, Hans-Peter
    CIRCULATION, 2007, 116 (16) : 466 - 466
  • [45] Acetylcholine-Induced Coronary Artery Spasm in Patients Treated with Drug-Eluting Stent is Different with De Novo Coronary Artery Spasm
    Park, Ji Young
    Rha, Seung-Woon
    Wang, Lin
    Poddar, Kanhaiya L.
    Ramasamy, Sureshkumar
    Choi, Byoung Geol
    Choi, Cheol Ung
    Park, Chang Gyu
    Seo, Hong Seog
    Oh, Dong Joo
    CIRCULATION, 2010, 122 (02) : E258 - E258
  • [46] Clinical outcome of patients with de novo coronary bifurcation lesions treated with the Tryton Side Branch Stent. The SAFE-TRY prospective multicenter single arm study
    Tarantini, Giuseppe
    La Vecchia, Luigi
    Galli, Mario
    Favero, Luca
    D'Amico, Gianpiero
    Buja, Paolo
    Russo, Filippo
    Cabianca, Ester
    Napodano, Massimo
    Musumeci, Giuseppe
    Franceschini, Enrico
    Grassi, Giuseppe
    Pavei, Andrea
    Bonmassari, Roberto
    Cernetti, Carlo
    Spedicato, Leonardo
    Caprioglio, Francesco
    Reimers, Bernhard
    Isabella, Giambattista
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2013, 168 (06) : 5323 - 5328
  • [47] Late Safety Efficacy, and Cost-Effectiveness of a Zotarolimus-Eluting Stent Compared With a Paclitaxel-Eluting Stent in Patients With De Novo Coronary Lesions 2-Year Follow-Up From the ENDEAVOR IV Trial (Randomized, Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary, Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions)
    Leon, Martin B.
    Kandzari, David E.
    Eisenstein, Eric L.
    Anstrom, Kevin J.
    Mauri, Laura
    Cutlip, Donald E.
    Nikolsky, Eugenia
    O'Shaughnessy, Charles
    Overlie, Paul A.
    Kirtane, Ajay J.
    McLaurin, Brent T.
    Solomon, Stuart L.
    Douglas, John S., Jr.
    Popma, Jeffrey J.
    JACC-CARDIOVASCULAR INTERVENTIONS, 2009, 2 (12) : 1208 - 1218
  • [48] A Clinical Evaluation of the Bioabsorbable Everolimus Eluting Coronary Stent System in the Treatment of Patients With De Novo Native Coronary Artery Lesions (vol 10, e004393, 2017)
    Onuma, Y.
    Grundeken, M. J.
    Nakatani, S.
    Asano, T.
    Sotomi, Y.
    Foin, N.
    Ng, J.
    Okamura, T.
    Wykrzykowska, J. J.
    de Winter, R. J.
    van Geuns, R. J.
    Koolen, J.
    Christiansen, Evald H.
    Whitbourn, R.
    McClean, D.
    Smits, P.
    Windecker, S.
    Ormiston, J. A.
    Serruys, P. W.
    CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2018, 11 (01)
  • [49] A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial
    Ormiston, John A.
    Serruys, Patrick W.
    Regar, Evelyn
    Dudek, Dariusz
    Thuesen, Leif
    Webster, Mark W. I.
    Onuma, Yoshinobu
    Garcia-Garcia, Hector M.
    McGreevy, Robert
    Veldhof, Susan
    LANCET, 2008, 371 (9616): : 899 - 907
  • [50] Long-term follow-up of the randomised controlled trial to evaluate the safety and efficacy of the zotarolimus-eluting driver coronary stent in de novo native coronary artery lesions: five year outcomes in the ENDEAVOR II study
    Fajadet, Jean
    Wijns, William
    Laarman, Gert-Jan
    Kuck, Karl-Heinz
    Ormiston, John
    Baldus, Stephan
    Hauptmann, Karl E.
    Suttorp, Maarten D.
    Drzewiecki, Janusz
    Pieper, Michael
    Schultheiss, Heinz-Peter
    Mauri, Laura
    EUROINTERVENTION, 2010, 6 (05) : 562 - 567
12345